Related Experiment Video

Updated: Feb 24, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.8K

[RNA interference targeting DNA-PKcs inhibits glioma cells malignancies and enhances temozolomide sensitivity]

Z H Zhang1, X Y Fan, Z T Zhao

  • 1Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China.

Zhonghua Yi Xue Za Zhi
|August 25, 2017
PubMed

Insights

Targeting DNA-PKcs (DNA dependent protein kinase catalytic subunit) with RNA interference inhibits glioma growth and invasion. This approach also enhances temozolomide sensitivity by downregulating the AKT signaling pathway, offering a potential therapeutic strategy for glioma.

Area of Science:

  • Molecular Biology
  • Oncology
  • Neuroscience

Background:

  • Glioma is a primary brain tumor with poor prognosis.
  • DNA dependent protein kinase catalytic subunit (DNA-PKcs) is implicated in DNA repair and cancer progression.
  • Temozolomide is a standard chemotherapeutic agent for glioma.

Purpose of the Study:

  • To investigate the role of DNA-PKcs in glioma proliferation, invasion, and temozolomide sensitivity.
  • To explore the underlying molecular mechanisms of DNA-PKcs's influence on glioma.

Main Methods:

  • RNA interference (siRNA) was used to knockdown DNA-PKcs in human glioma cell lines (H4 and U87).
  • Quantitative PCR and Western blot confirmed knockdown efficacy.
  • MTS and Transwell assays assessed cell proliferation, invasion, and temozolomide sensitivity (IC50 values).

Main Results:

  • DNA-PKcs knockdown significantly reduced glioma cell proliferation and invasion.
  • Knockdown of DNA-PKcs decreased temozolomide IC50 values, indicating enhanced sensitivity.
  • Downregulation of DNA-PKcs led to reduced AKT signaling and expression of downstream effectors (c-Myc, MMP9, Survivin).

Conclusions:

  • Targeting DNA-PKcs via RNA interference inhibits glioma malignancy.
  • DNA-PKcs knockdown enhances temozolomide sensitivity in glioma cells.
  • The observed effects are mediated through the inhibition of the AKT signaling pathway.
Keywords:
GliomaInvasionRNA interferenceTemozolomide

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K